Technische Universität Dresden: Leukemia, Myeloid, Acute trials
The registry lists 19 Leukemia, Myeloid, Acute studies with Technische Universität Dresden as lead sponsor. 5 are open to participants now and 0 have results posted.
Phase 1 3Phase 2 12Phase 3 1Phase 4 3No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic TransplantationRecruitingNCT07025824Phase 2
- Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive TreatmentRecruitingNCT06696183Phase 2
- Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AMLRecruitingNCT05904106Phase 2
- Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)RecruitingNCT04385290Phase 1/2
- Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)RecruitingNCT03188874
- Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)CompletedNCT04330820Phase 1/2
- MRD-guided Treatment in NPM1mut AML PatientsTerminatedNCT03769532Phase 2
- Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AMLTerminatedNCT02229266Phase 2
- Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AMLCompletedNCT02140242Phase 3
- Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AMLCompletedNCT01830361Phase 2
- Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)CompletedNCT01462578Phase 2
- Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)CompletedNCT01295307Phase 2
- PET-CT in AML for Detection of Extramedullary AML ManifestationsCompletedNCT01278069
- Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic SyndromesTerminatedNCT00923234Phase 1
- Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of AgeCompletedNCT00893373Phase 2
- Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)TerminatedNCT00720850Phase 2
- Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraCCompletedNCT00180167Phase 4
- AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia PatientsCompletedNCT00180115Phase 4
- AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 YearsCompletedNCT00180102Phase 4